Detection of treated liver metastases using fluorine-18-fluordeoxyglucose (FDG) and positron emission tomography (PET).
The aim of the study was the evaluation of the detectability of treated liver metastases using one FDG-PET measurement. The study includes 42 patients (80 lesions) from different primary tumours. Standardized Uptake Values (SUV) as well as the tumour to liver Ratio (T/L) were used for evaluation. A T/L > 1.0 was considered to be pathological. Clinical follow-up data for at least 6 months were used as a reference. The median value of the FDG-uptake was 2.9 SUV in all liver metastases. The sensitivity based on a T/L ratio exceeding 1.0 was 82.5% (66/80 lesions). 25 of 80 (31%) lesions had a ratio T/L higher than 2.0 and were clearly visualized by PET. Negative results with a ratio T/L < 1.0 were raised in 14 of 80 treated metastatic lesions (17.5%). Although these metastases were hypometabolic, they were correctly classified due to the image correlation with computed tomography (CT) or magnetic resonance (MR) images or due to a baseline FDG-study prior to the onset of therapy. False positive results were not noted in this study. FDG-PET is a reliable method for the evaluation of treated liver metastases. A baseline FDG study prior to therapy is preferable for the interpretation.
Mantaka
P
P
Department of Oncological Diagnostics and Therapy, German Cancer Research Center, Heidelberg, Germany.
Strauss
A D
AD
Strauss
L G
LG
Moehler
M
M
Goldschmidt
H
H
Oberdorfer
F
F
Kontaxakis
G
G
Van Kaick
G
G
D001786:Blood Glucose / Q000032:analysis; D005069:Evaluation Studies as Topic; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000000981:diagnostic imaging* / Q000556:secondary*; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed / Q000379:methods
D001786:Blood Glucose; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18